Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT)

Y. Udagawa, Daisuke Aoki, K. Ito, T. Uejima, M. Uemura, S. Nozawa

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In this study clinical studies were conducted on galactosyltransferase associated with tumour (GAT) as a newly developed marker of ovarian cancers. The positive rates of GAT with a cut-off value of 16 U/ml (which corresponds to the mean + 2 standard deviations (S.D.) for healthy females) were 4.7% for benign ovarian tumours, 4.5% for endometriosis and 45.9% for ovarian cancers. GAT showed a positive rate comparable to that of CA546 or CA72-4 among other tumour markers (CA602, CA125, CA546, CA724, STN and SLX) examined in ovarian cancers. However, it showed lower positive rates for benign ovarian diseases and, in particular, it gave the lowest positive rate for endometriosis Among the aforementioned tumour markers. Furthermore, the receiver operating characteristic (ROC) analysis for discriminating between ovarian cancer and endometriosis showed a significantly high area under the curve (AUG) for GAT compared with that of the other markers. GAT showed the lowest correlation coefficients with other markers, and the positive rate and the diagnostic efficiency were increased by its combination assay with CA602 and/or CA546. Furthermore, the accuracy of the diagnosis of ovarian cancer improved by examining GAT after screening with CA602 or ultrasonography. These results suggest that GAT is a suitable marker for distinguishing ovarian cancers from benign gynaecological diseases, particularly endometriosis, and is useful for combination assay or secondary screening for ovarian cancers.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalEuropean Journal of Cancer
Volume34
Issue number4
DOIs
Publication statusPublished - 1998 Mar

Fingerprint

Galactosyltransferases
Tumor Biomarkers
Ovarian Neoplasms
Endometriosis
Neoplasms
Ovarian Diseases
ROC Curve
Area Under Curve
Ultrasonography

Keywords

  • Combination assay
  • Galactosyltransferase
  • GAT
  • Ovarian cancer
  • Tumour marker

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT). / Udagawa, Y.; Aoki, Daisuke; Ito, K.; Uejima, T.; Uemura, M.; Nozawa, S.

In: European Journal of Cancer, Vol. 34, No. 4, 03.1998, p. 489-495.

Research output: Contribution to journalArticle

@article{785e40d4253143398f6472059e45ac43,
title = "Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT)",
abstract = "In this study clinical studies were conducted on galactosyltransferase associated with tumour (GAT) as a newly developed marker of ovarian cancers. The positive rates of GAT with a cut-off value of 16 U/ml (which corresponds to the mean + 2 standard deviations (S.D.) for healthy females) were 4.7{\%} for benign ovarian tumours, 4.5{\%} for endometriosis and 45.9{\%} for ovarian cancers. GAT showed a positive rate comparable to that of CA546 or CA72-4 among other tumour markers (CA602, CA125, CA546, CA724, STN and SLX) examined in ovarian cancers. However, it showed lower positive rates for benign ovarian diseases and, in particular, it gave the lowest positive rate for endometriosis Among the aforementioned tumour markers. Furthermore, the receiver operating characteristic (ROC) analysis for discriminating between ovarian cancer and endometriosis showed a significantly high area under the curve (AUG) for GAT compared with that of the other markers. GAT showed the lowest correlation coefficients with other markers, and the positive rate and the diagnostic efficiency were increased by its combination assay with CA602 and/or CA546. Furthermore, the accuracy of the diagnosis of ovarian cancer improved by examining GAT after screening with CA602 or ultrasonography. These results suggest that GAT is a suitable marker for distinguishing ovarian cancers from benign gynaecological diseases, particularly endometriosis, and is useful for combination assay or secondary screening for ovarian cancers.",
keywords = "Combination assay, Galactosyltransferase, GAT, Ovarian cancer, Tumour marker",
author = "Y. Udagawa and Daisuke Aoki and K. Ito and T. Uejima and M. Uemura and S. Nozawa",
year = "1998",
month = "3",
doi = "10.1016/S0959-8049(97)10079-X",
language = "English",
volume = "34",
pages = "489--495",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT)

AU - Udagawa, Y.

AU - Aoki, Daisuke

AU - Ito, K.

AU - Uejima, T.

AU - Uemura, M.

AU - Nozawa, S.

PY - 1998/3

Y1 - 1998/3

N2 - In this study clinical studies were conducted on galactosyltransferase associated with tumour (GAT) as a newly developed marker of ovarian cancers. The positive rates of GAT with a cut-off value of 16 U/ml (which corresponds to the mean + 2 standard deviations (S.D.) for healthy females) were 4.7% for benign ovarian tumours, 4.5% for endometriosis and 45.9% for ovarian cancers. GAT showed a positive rate comparable to that of CA546 or CA72-4 among other tumour markers (CA602, CA125, CA546, CA724, STN and SLX) examined in ovarian cancers. However, it showed lower positive rates for benign ovarian diseases and, in particular, it gave the lowest positive rate for endometriosis Among the aforementioned tumour markers. Furthermore, the receiver operating characteristic (ROC) analysis for discriminating between ovarian cancer and endometriosis showed a significantly high area under the curve (AUG) for GAT compared with that of the other markers. GAT showed the lowest correlation coefficients with other markers, and the positive rate and the diagnostic efficiency were increased by its combination assay with CA602 and/or CA546. Furthermore, the accuracy of the diagnosis of ovarian cancer improved by examining GAT after screening with CA602 or ultrasonography. These results suggest that GAT is a suitable marker for distinguishing ovarian cancers from benign gynaecological diseases, particularly endometriosis, and is useful for combination assay or secondary screening for ovarian cancers.

AB - In this study clinical studies were conducted on galactosyltransferase associated with tumour (GAT) as a newly developed marker of ovarian cancers. The positive rates of GAT with a cut-off value of 16 U/ml (which corresponds to the mean + 2 standard deviations (S.D.) for healthy females) were 4.7% for benign ovarian tumours, 4.5% for endometriosis and 45.9% for ovarian cancers. GAT showed a positive rate comparable to that of CA546 or CA72-4 among other tumour markers (CA602, CA125, CA546, CA724, STN and SLX) examined in ovarian cancers. However, it showed lower positive rates for benign ovarian diseases and, in particular, it gave the lowest positive rate for endometriosis Among the aforementioned tumour markers. Furthermore, the receiver operating characteristic (ROC) analysis for discriminating between ovarian cancer and endometriosis showed a significantly high area under the curve (AUG) for GAT compared with that of the other markers. GAT showed the lowest correlation coefficients with other markers, and the positive rate and the diagnostic efficiency were increased by its combination assay with CA602 and/or CA546. Furthermore, the accuracy of the diagnosis of ovarian cancer improved by examining GAT after screening with CA602 or ultrasonography. These results suggest that GAT is a suitable marker for distinguishing ovarian cancers from benign gynaecological diseases, particularly endometriosis, and is useful for combination assay or secondary screening for ovarian cancers.

KW - Combination assay

KW - Galactosyltransferase

KW - GAT

KW - Ovarian cancer

KW - Tumour marker

UR - http://www.scopus.com/inward/record.url?scp=0032033782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032033782&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)10079-X

DO - 10.1016/S0959-8049(97)10079-X

M3 - Article

C2 - 9713298

AN - SCOPUS:0032033782

VL - 34

SP - 489

EP - 495

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -